00:01:11
High-risk regulatory claim
identifies GLP-1 drugs/brands and their uses.
Review topic: semaglutide / class.
Checked against: Wegovy prescribing information
Video claim watch
What Ozempic & Weight Loss Drugs Really Do to the Body
High-view (2.9M+) anatomy-focused explainer on physiological effects of GLP-1 drugs.
Institute of Human Anatomy channel20:00 runtime3M views when checked
Transcript review
7 material claims logged
Editorial review complete audit stateauto-captioned transcript0 operational-guidance flags0 source gaps
Reviewed Jul 12, 2026. Next review Aug 12, 2026.
well-structured class explainer; compounding/cost section needs regulatory precision.
auto-caption available; 17 creator chapters.
Claim-by-claim audit
What the video says, and what needs checking
00:03:15
Mechanism
explains pancreatic insulin/glucagon effects and 00:04:04 appetite/gastric effects.
Review topic: mechanism.
Checked against: Wegovy prescribing information
00:05:22
High-risk evidence claim
reports semaglutide half-life, use, and efficacy.
Review topic: semaglutide pharmacology.
Checked against: Once-weekly semaglutide in adults with overweight or obesity, Wegovy prescribing information
00:06:36
High-risk evidence claimHigh-risk regulatory claim
claims cardiovascular-risk reduction.
Review topic: CV outcomes.
Checked against: FDA approves Wegovy cardiovascular risk reduction indication
00:07:27
High-risk safety claim
covers common and serious adverse effects.
Review topic: semaglutide safety.
Checked against: Wegovy prescribing information
00:09:22
High-risk evidence claimHigh-risk regulatory claimHigh-risk quality claim
raises lean-mass loss; 00:09:45 contrasts branded cost and compounding.
Review topic: body composition / access.
Checked against: Impact of semaglutide on body composition in STEP 1, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss., FDA alert on dosing errors associated with compounded injectable semaglutide
00:14:44
High-risk evidence claim
warns of weight regain after discontinuation.
Review topic: withdrawal.
Checked against: Weight regain and cardiometabolic effects after withdrawal of semaglutide
Connected research
Compounds discussed
Source check
Records used in this claim audit
Wegovy prescribing information
FDA prescribing information for Wegovy.
7 linked pagesOpen original ·
fda-wegovy-label-2025Once-weekly semaglutide in adults with overweight or obesity
Randomized STEP 1 trial of semaglutide in adults with overweight or obesity.
6 linked pagesOpen original ·
nejm-semaglutide-step1-2021-videoFDA approves Wegovy cardiovascular risk reduction indication
FDA announcement of the cardiovascular risk-reduction indication for Wegovy in eligible adults.
3 linked pagesOpen original ·
fda-wegovy-cardiovascular-indication-2024Impact of semaglutide on body composition in STEP 1
Exploratory STEP 1 body-composition substudy. Lean mass is not equivalent to skeletal muscle.
4 linked pagesOpen original ·
pmc-step1-body-composition-2021FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Accessed 2026-07-12.
11 linked pagesOpen original ·
research-reta-02FDA alert on dosing errors associated with compounded injectable semaglutide
FDA alert describing reported dosing errors associated with compounded injectable semaglutide products.
1 linked pageOpen original ·
fda-compounded-semaglutide-dosing-errors-2024Weight regain and cardiometabolic effects after withdrawal of semaglutide
STEP 1 extension reporting weight regain after semaglutide withdrawal.
2 linked pagesOpen original ·
pubmed-step1-withdrawal-2022